Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis

BACKGROUND: Currently, blockade of the programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) signaling pathway has been proved one of the most promising immunotherapeutic strategies against cancer. Several antibodies have been developed to either block the PD-1 or its ligand PD-L1 are under developme...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Thorac Dis
Hauptverfasser: Jia, Minghan, Feng, Weijiao, Kang, Shiyang, Zhang, Yaxiong, Shen, Jianfei, He, Jiaxi, Jiang, Long, Wang, Wei, Guo, Zhihua, Peng, Guilin, Chen, Gang, He, Jianxing, Liang, Wenhua
Format: Artigo
Sprache:Inglês
Veröffentlicht: AME Publishing Company 2015
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4387409/
https://ncbi.nlm.nih.gov/pubmed/25922725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2072-1439.2015.02.06
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge